Objective: We sought to develop and validate a risk index for prospective cognitive decline in older adults based on blood-derived markers.
dementias are the result of mixed pathology, potentially accelerated by comorbidities 6 : APOE e4, b-amyloid 42/40 ratio, telomere length, blood glucose, cystatin C, C-reactive protein (CRP), interleukin-6, and albumin.
Previous studies have sought combinations of blood-based markers that differentiated between dementia and control groups. 7, 8 We have expanded on this by looking for indicators that precede cognitive decline, potentially more useful for research and clinical care. Using a development sample of older adults, we created a risk index using blood-based markers. Then, we evaluated how strongly the index was associated with cognitive decline in a validation sample from the same cohort. METHODS 
Participants. Recruitment for the Health, Aging
and Body Composition (Health ABC) Study, a prospective cohort of 3,075 community-dwelling older adults, occurred in 1997-1998. Participants were recruited from a random sample of Medicare-eligible white adults and all black Medicare-eligible residents living within specific zip codes in Pittsburgh, PA, and Memphis, TN. Eligibility required no difficulties performing activities of daily living, walking a quarter mile, or climbing 10 steps without resting and intending to remain in the study area for at least 3 years. Potential participants with life-threatening cancers were excluded. 9 To avoid including participants with prevalent dementia, participants with a baseline Modified Mini-Mental State Examination (3MS) cognitive score ,80 were excluded, along with individuals without at least 2 cognitive testing time points. We used a stratified random sample based on race, sex, and age (,75/751) to create two-thirds of the observations as a development sample (n 5 1,632), reserving the other third for a validation sample (n 5 833). Missing values for primary markers left us with a final analytic sample of n 5 1,445 in the development data and n 5 739 in the validation data.
Standard protocol approvals, registrations, and patient consents. The Health ABC Study protocol was approved by institutional review boards at both clinical sites (University of Pittsburgh, University of Tennessee, Memphis) and the University of California-San Francisco coordinating center. All participants signed informed consent at enrollment.
Outcome. Cognition was assessed with the 3MS, measured at years 1, 3, 5, 8, 10, and 11. 10 The primary outcome for this analysis was changeover time on the 3MS cognitive test. We calculated person-specific slopes (best linear unbiased predictors) from a linear mixed-effects regression model based on the entire available sample. 11 Markers. The risk index components we examined included APOE e4, b-amyloid 42/40 ratio, telomere length, blood glucose, cystatin C, CRP, interleukin-6 (IL-6), and albumin. APOE e4 is the strongest known genetic risk factor for AD and all-cause dementia, increasing risk of AD by 3-fold. 12, 13 However, the e4 allele is neither necessary nor sufficient for the development of cognitive decline. The ratio of plasma b-amyloid 42 to b-amyloid 40 has been previously found to be predictive of AD and all-cause dementia in meta-analysis. 14 Telomere length (thought to have a role in aging in general) has been associated with cognitive decline and dementia in a number of older populations. [15] [16] [17] Diabetes and poor glucose regulation, often marked by elevated fasting blood glucose, have been consistently associated with poor cognitive outcomes. 18 High cystatin C, a marker for poor kidney function, has also been previously associated with cognitive deficit. 19 There is substantial evidence that inflammation has a role in cognitive aging, possibly through a vascular pathway. CRP is a strong risk factor for vascular disease (which is itself a risk factor for dementia) but results linking CRP to cognition conflict with some studies showing a significant association and others failing to find an association. 20, 21 High levels of IL-6 have been associated with worse cross-sectional cognitive performance and cognitive decline. 22, 23 Low levels of serum albumin have been cross-sectionally associated with cognitive impairment in older adults, and there is evidence that serum albumin may have a role in reducing b-amyloid toxicity. 24, 25 Nearly all of the markers used in this analysis were measured in the entire Health ABC cohort, although plasma b-amyloid was measured in a subset of 998 participants (random sample of race and sex) who had more than one cognitive test measure.
Baseline fasting blood samples were obtained in the morning via standard venipuncture; after processing, the specimens were aliquoted, frozen at 270°C, and shipped to the Health ABC Core Laboratory at the University of Vermont (Burlington). Serum cystatin C was measured using a BNI nephelometer (Dade Behring, Deerfield, IL) that used a particle-enhanced immunonephelometric assay (N Latex cystatin C). The assay range is 0.195 to 7.33 mg/L. Plasma IL-6 level was measured in duplicate using ELISA kits (R&D Systems, Minneapolis, MN), with detectable limit of 0.10 pg/mL. Serum CRP level was measured in duplicate using ELISA based on purified protein and polyclonal anti-CRP antibodies (Calbiochem, EMD Biosciences Inc., Darmstadt, Germany). The CRP assay was standardized according to the World Health Organization First International Reference Standard with a sensitivity of 0.08 mg/ mL. Albumin was measured with a colormetric technique on a Johnson & Johnson Vitros 950 analyzer (New Brunswick, NJ). Plasma glucose was measured by an automated glucose oxidase reaction (YSI 2300 Glucose Analyzer; Yellow Springs Instruments, Yellow Springs, OH).
Telomere length was measured at the University of Utah using DNA extracted from blood leukocytes; average telomere lengths were measured by quantitative PCR. Relative average telomere lengths were determined by comparing each DNA sample with a reference DNA sample using the standard curve method with coefficient of variation of 5.8%. 26 b-Amyloid 40 and b-amyloid 42 were measured from stored plasma obtained at the first follow-up visit (year 2) at the laboratory of Dr. Steven G. Younkin at the Mayo Clinic, Jacksonville, FL, using Innogenetics (Ghent, Belgium) INNO-BIA assays. Detection limits for this assay are 12 pg/mL for b-amyloid 40 (interassay coefficient of variation 5 9.9%, mean within-assay coefficient of variation 5 3.5%) and 5 pg/mL for b-amyloid 42 (interassay coefficient of variation 5 9.3%, mean interassay coefficient of variation 5 2.3%).
Statistical analysis. The development and validation datasets
were compared for differences in demographics and blood marker distributions. Frequencies and percentages are reported for demographics; reported p values were obtained from x 2 tests. We reported medians, ranges, and p values from nonparametric tests for blood markers, because many were substantially skewed.
Index development methods. Before constructing the index, we dichotomized each continuous marker using bootstrapped area under the curve analysis at a cutoff predictive of substantial cognitive decline, which we defined as having a 3MS slope in the lowest quartile for the entire analytic sample; this corresponded to approximately 0.8 points lost annually. Although accepted clinical cutoffs exist for some of the markers, none were designed to target preclinical decline. To evaluate the strength of association between the dichotomized markers and cognitive decline before constructing the index, we used individual linear regression models with robust standard errors using person-specific slopes as the outcome.
We created a weighted risk score based on logistic regression coefficients using the same weighting methodology as in the latelife dementia index of Barnes et al. 27 where markers with b coefficients .0.75 were given a weight of 2 and all other markers were given a weight of 1. Preliminary analysis suggested that plasma amyloid 42/40 ratio was the strongest predictor for cognitive decline, but it was measured on a smaller subset of subjects. We chose to exclude amyloid from the primary index to avoid a substantial sample size reduction; however, we created a secondary index that includes amyloid. Both the primary and secondary risk indexes were divided into low-, medium-, and high-risk ranges based on the cognitive slope distribution at each level of the index in the development data.
Index validation methods. We evaluated the association between the low-, medium-, and high-risk categories and cognitive decline (person-specific 3MS slope) using linear regression models, with and without adjustment for age and baseline 3MS, to evaluate whether the indexes were determining clinically apparent baseline differences or actually predictive of prospective cognitive decline.
Analysis was performed using all available complete cases with SAS version 9.3 (SAS Institute, Cary, NC) and R version 3.0.0. Table 1 describes the participants in the development and validation samples. The 2 samples do not significantly differ on demographic characteristics, markers, or number of cognitive assessments.
RESULTS
Development results. Cutpoints for the dichotomized blood markers ranged from the 38th to the 87th percentile in the development data (table 2) . All of the dichotomized markers were significantly associated with cognitive decline in the development data.
Weights for the primary and secondary indexes were derived with 2 separate logistic regression models using membership in the lowest slope quartile as the outcome (table 2) . The primary index resulted in equal weights for all markers. The secondary index (amyloid) resulted in a weight of 2 for amyloid and a weight of 1 for all other markers. Linear trend tests for both indexes were highly significant (p , 0.0001). Low-, medium-, and high-risk categories were created based on the person-specific cognitive slope distribution in the development data. For the primary index (potential range 0-7), a score of 0-1 was considered low risk, 2-3 was medium risk, and 4-7 was high risk. For the secondary index (potential range 0-9), a score of 0-2 was low risk, 3-5 was medium risk, and 6-9 was high risk. 
DISCUSSION
We found that the low-, medium-, and high-risk categories in both our primary and secondary indexes were significantly associated with longitudinal cognitive decline independent of age. The risk indexes were predictive with modest effect sizes (approximately 0.4 3MS points per year difference between high-and low-risk groups) even when controlling for baseline 3MS, which suggests that the indexes can provide valuable predictive information about future cognitive trajectories in addition to what could be inferred using baseline cognitive status. Although there is not a universally agreed on definition of meaningful clinical change on the 3MS, a 5-point change has been suggested and used in previous studies. 3, [28] [29] [30] Based on the average annual change in age-adjusted analysis, the low-risk group would reach a 5-point change after more than 14 years and the high-risk group would reach such a point in less than 7 years. We chose to combine 8 markers representing a variety of pathways associated with cognitive decline ranging from markers of general aging (telomere length) to AD-specific markers (APOE, amyloid). We also emphasized markers for inflammation (CRP, IL-6) and vascular pathways (glucose, cystatin C) because previous studies have demonstrated a strong role for both in AD and all-cause dementia. 7, 31, 32 Albumin performs a number of functions that may influence cognitive decline on multiple pathways including antioxidant defense, inhibition of b-amyloid-peptide fibrils, and transport of metals, fatty acids, cholesterol, and drugs. 33, 34 We were interested to find that the cutoff percentile for what qualified as the at-risk level of the blood markers varied widely between markers, encompassing less than 15% to as much as 85% of the development sample. Our cutoff results may be useful to other researchers examining the relationship between these markers and cognitive decline or dementia; often such markers are categorized based on simple percentiles because of a lack of a priori information on informative groupings. We were interested to find that, in many cases, our cutoffs were similar to clinical cutoffs used; our blood glucose cutoff was 107.5 mg/dL and the 2012 International Diabetes Federation guidelines list 126 mg/ dL as a cutoff of concern. 35 Similarly, our cystatin-C cutoff of 1.235 mg/L was near the cutoff used for preclinical kidney disease (.1.0 mg/L). 36 Our analysis had a number of limitations. Our primary outcome, person-specific 3MS slope, was derived using best linear unbiased predictors from a longitudinal regression model across more than 10 years of follow-up, which has many advantages over a simpler change score model. However, slope estimates in individuals with fewer cognitive observations were shrunk in magnitude toward the overall average, relative to individuals with more observations. 11 This is a conservative approach but risks the possibility that individuals lost to follow-up earlier, potentially because of cognitive decline, were assigned a slope that did not reflect the full degree of their impairment. Although the b-amyloid 42/40 ratio was one of the most predictive markers, it was only available on a subset of the participants, reducing the precision of our estimates. We chose a fairly straightforward weighting scheme for the construction of the index to make the index easy to use, but a sensitivity analysis using an alternate approach with exact logistic regression coefficients for each marker resulted in similar performance in the development data. We used separate development and validation samples, but both were from the same cohort; further validation will be necessary in other populations. One unambiguous benefit of the primary index is that all of the components could be measured inexpensively from a single blood draw and do not require research staff with specialized training for components such as neuropsychological testing or additional procedures such as imaging. Therefore, this risk index could be used affordably in large cohort studies. This could be especially useful for studies that are designed to closely monitor participants as they undergo biological and clinical changes associated with cognitive decline. Likewise, the risk index could be used in a research setting to seed a prevention trial with individuals who are more likely to exhibit decline, thereby providing a greater opportunity to observe the effect of the intervention. The risk index could be used in a clinical setting, combined with patient/informant report, family history, and the Barnes et al. 27 late-life dementia risk index (which focuses on demographics, health history, medical imaging, and cognitive testing), to provide a more comprehensive risk profile for cognitive decline. This would allow clinical practitioners to closely monitor high-risk patients for cognitive change, initiate treatment at an earlier stage, and encourage tighter control of conditions that are risk factors for dementia, such as hypertension and diabetes. A risk profile could help inform patients' medical and financial planning and potentially provide motivation for lifestyle changes associated with cognitive resilience, such as more exercise and social engagement.
Our results have demonstrated internal validity of the risk indexes in this cohort and have shown promise in identifying prospective cognitive change independent of baseline cognitive status. Further study in other populations is necessary to determine whether these indexes have robust external validity. Nearly all of the components of our indexes are time-varying, thereby allowing an individual's risk category to vary over time. Future studies with repeated laboratory measures will be needed to evaluate whether changes in the index track with cognitive performance over time. If so, the risk index could have even greater value as a clinical monitoring device.
